期刊文献+

加替沙星、雷贝拉唑治疗幽门螺杆菌阳性十二指肠溃疡疗效观察 被引量:1

下载PDF
导出
摘要 目的观察以加替沙星与雷贝拉唑为主的三联疗法根除幽门螺杆菌(Hp)的疗效、不良反应和十二指肠溃疡复发率,以探讨临床更佳的根除Hp方案,提高十二指肠溃疡治愈率,降低复发率。方法选择符合条件270例患者,随机分为A、B、C组。A组加替沙星200mg bid,雷贝拉唑10mg bid,阿莫西林500mg bid。B组克拉霉素500mg bid,奥美拉唑20mg bid,甲硝唑200mg bid。C组阿莫西林500mg bid,奥美拉唑20mg bid,克拉霉素500mg bid。以上3组疗程均为10d。之后为雷贝拉唑10mg bid,果胶铋150mgtid共服用4周。停药4周后复查胃镜及14C-呼气试验。6月后复查胃镜。结果A组、B组、C组Hp根除率分别为93%、88%、92%,溃疡愈合率100%,96%,98%。溃疡复发率3%,4%,5%。3组相比无统计学意义,未见严重不良反应。结论加替沙星、雷贝拉唑为主的三联疗法能有效、安全根除幽门螺杆菌,且能提高十二指肠溃疡治愈率,降低复发率。
出处 《中外医疗》 2009年第29期84-85,共2页 China & Foreign Medical Treatment
  • 相关文献

参考文献6

  • 1Boyanova L,Mentis A,Gubina M,et al.The status of antimicrobial resistance of helicobacter pyrpli in eastern Europe[J].ClinMicrobiol Infect,2002,8(7):388.
  • 2钟英强,许哲,夏忠胜,陈其奎,曾志勇,黄志清.以加替沙星为基础的三联疗法根除幽门螺杆菌感染的疗效和费用分析[J].中国新药与临床杂志,2005,24(5):394-397. 被引量:19
  • 3Kawakami Y, Akahane T, Yamaguchi M,et al.In viro activities of rabeprazole,a novel proton pump inhibitor and itsthioether derivative alone and combination with other antimicobials against recent clinical isolates of Helicobacter pylori[J].Antimicrob Agest Chemother,2000,44:458.
  • 4郑青,吴叔明,柯美云,刘晓红,刘南植,但自力,苌新明,房殿春,肖天力,萧树东.雷贝拉唑与奥美拉唑三联疗法根除幽门螺杆菌多中心、随机、双盲、平行对照研究[J].胃肠病学,2002,7(5):272-276. 被引量:62
  • 5Richardson P, Hawky CJ,Stack A.Proton pump inhititors:pharmacology and rationale for use in gestrointestinal disorders[J].Drugs, 1998.56:307.
  • 6Obsquse-Padilla FJ,Garza-gonzalez E,Galderonlozano IE,et al.Open, randomized multicenter comparative trial of rabeprazole,ofloxacin and amoxicillin therapy for Helicobater pylorieradication;7 vs 14 day treatment[J].Helicobacter,2004,9(5):417.

二级参考文献31

  • 1CAMMAROTA G, CIANCI R, CANNIZZARO O, et al. High-dose versus low-dose clarithromycin in 1-week triple therapy, including rabeprazole and levefloxacin, for Helicobacter pylorieradication [J].J Clin Gastroenterol, 2004,38 (2): 110-114.
  • 2BOSQUES-PADILLA FJ, GARZA-GONZALEZ E, CALDERONLOZANO IE, et al. Open, randomized multicenter comparative trial of rabeprazole, ofloxacin and amoxicillin therapy for Helicobacter pylori eradication:7 vs 14 day treatment [J]. Helicobacter, 2004,9(5) :417-421.
  • 3FISH DN, NORTH DS. Gatifloxacin, an advanced 8-methory fluoroquinolone [J]. Pharmacotherapy, 2001,21 (1) :35-59.
  • 4SARAVOLATZ LD, LEGGETT J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolone [J]. Clin Infect Dis, 2003,37(9) :1210-1215.
  • 5KHURANA A, VINAYEK N, RECCO RA, et al. The incidence of clostridium diffile-associated and non-C. diffile-associated doarrhea after use of gatifloxacin and levofloxacin in an acute-care facility [J]. Clin Infect Dis, 2004,39(4) :602-603.
  • 6GRASELA DM, CHRISTOFALO B, KOLLIA GD, et al. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment [J]. Pharmacotherapy,2000,20 (6Pt2) :87S-94S.
  • 7HENANN NE, ZAMBIE MF. Gatifloxacin-asociated acute hepatitis [J]. Pharmacotherapy, 2001,21 (12): 1579-1582.
  • 8CHEUNG O, CHOPRA K, YU T, et al. Gatifloxacin-induced hepatotoxicity and acute pancreatitis [J]. Ann Intern Med, 2004,140(1) :73-74.
  • 9LOMAESTRO BM. Fluoroquinolone-induced renal failure [J].Drug Saf, 2000,22(6) :479-485.
  • 10LEBLANC M, BELANGER C, COSSETTE P. Severe and resistant hypoglycemia associated with concomitant gatifloxacin and glyburide therapy [J]. Pharmacotherapy, 2004,24 (7) :926-931.

共引文献78

同被引文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部